Tvardi Therapeutics, Inc. has made a significant stride in its drug development efforts by advancing TTI-109, an oral STAT3 inhibitor, toward an Investigational New Drug (IND) application. This announcement, made on November 19, 2026, follows positive feedback from the U.S. Food and Drug Administration (FDA) regarding the company's plans for Phase 2 clinical trials in inflammatory bowel disease (IBD).

The progress of TTI-109 is particularly noteworthy as it targets ulcerative colitis (UC) and Crohn's disease (CD), two major forms of IBD. The FDA's responses to Tvardi's pre-IND meeting request indicate that the agency supports the company's development approach and has provided guidance on various aspects, including dosing and patient selection.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral therapies targeting STAT3, a key protein involved in immune responses and inflammation. The company is publicly traded under the ticker symbol TVRD on the Nasdaq exchange. Its recent filings include an 8-K on November 19, 2026, detailing the FDA's feedback, and a 10-Q on November 13, 2026, providing updates on its financial performance.

What the Filing Says

According to the filing, "On November 19, 2026, Tvardi Therapeutics, Inc. issued a press release entitled 'Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback.'" The press release highlights the FDA's constructive feedback, which supports Tvardi's plans for further clinical development.

Impact

This development may significantly affect patients suffering from IBD, as TTI-109 aims to offer a new treatment option. The FDA's guidance allows Tvardi to proceed with confidence in its clinical trials, potentially leading to new therapies that could improve patient outcomes in this area. The pharmaceutical preparations industry could see increased competition as Tvardi moves forward with its IND submission and clinical trials.

What's Next

Tvardi plans to incorporate the FDA's feedback into its IND submission, expected in 2027. The initiation of the Phase 2 study will depend on the FDA's review and clearance of the IND submission, as well as the availability of additional funding.